These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 7932810

  • 1. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators.
    Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, Allasia C, Horschowski N, Piana L.
    J Natl Cancer Inst; 1994 Oct 19; 86(20):1539-45. PubMed ID: 7932810
    [Abstract] [Full Text] [Related]

  • 2. CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors.
    Charpin C, Devictor B, Bergeret D, Andrac L, Boulat J, Horschowski N, Lavaut MN, Piana L.
    Am J Clin Pathol; 1995 Apr 19; 103(4):443-8. PubMed ID: 7726141
    [Abstract] [Full Text] [Related]

  • 3. Determining MDR1/P-glycoprotein expression in breast cancer.
    Faneyte IF, Kristel PM, van de Vijver MJ.
    Int J Cancer; 2001 Jul 01; 93(1):114-22. PubMed ID: 11391630
    [Abstract] [Full Text] [Related]

  • 4. Automated and quantitative immunocytochemical assays of Bcl-2 protein in breast carcinomas.
    Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Lavaut MN, Allasia C.
    Br J Cancer; 1997 Jul 01; 76(3):340-6. PubMed ID: 9252201
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis.
    Suwa H, Ohshio G, Arao S, Imamura T, Yamaki K, Manabe T, Imamura M, Hiai H, Fukumoto M.
    Jpn J Cancer Res; 1996 Jun 01; 87(6):641-9. PubMed ID: 8766529
    [Abstract] [Full Text] [Related]

  • 6. No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer.
    Hegewisch-Becker S, Staib F, Löning T, Pichlmeier U, Kröger N, Reymann A, Hossfeld DK.
    Ann Oncol; 1998 Jan 01; 9(1):85-93. PubMed ID: 9541688
    [Abstract] [Full Text] [Related]

  • 7. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
    Schneider J, Rubio MP, Barbazán MJ, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS.
    J Natl Cancer Inst; 1994 Jun 01; 86(11):850-5. PubMed ID: 7910219
    [Abstract] [Full Text] [Related]

  • 8. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.
    Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB.
    J Natl Cancer Inst; 1992 Oct 07; 84(19):1486-91. PubMed ID: 1359152
    [Abstract] [Full Text] [Related]

  • 9. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.
    Ludescher C, Hilbe W, Eisterer W, Preuss E, Huber C, Gotwald M, Hofmann J, Thaler J.
    J Natl Cancer Inst; 1993 Nov 03; 85(21):1751-8. PubMed ID: 8105101
    [Abstract] [Full Text] [Related]

  • 10. Expression of multidrug resistance-related transporters in human breast carcinoma.
    Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y.
    Jpn J Cancer Res; 2001 Apr 03; 92(4):452-8. PubMed ID: 11346468
    [Abstract] [Full Text] [Related]

  • 11. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
    Punyammalee B, Manoromana S, Purisa W, Chariyalertsak S, Rerkamnuaychok B.
    J Med Assoc Thai; 1997 Sep 03; 80 Suppl 1():S162-73. PubMed ID: 9347665
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Expression of the multidrug-resistance gene product in untreated human breast cancer and its relationship to prognostic markers.
    De La Torre M, Larsson R, Nygren P, Lindgren A, Bergh J.
    Acta Oncol; 1994 Sep 03; 33(7):773-7. PubMed ID: 7993645
    [Abstract] [Full Text] [Related]

  • 19. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein.
    Moriki T, Takahashi T, Tanioka F, Yamane T, Hara H.
    Pathol Res Pract; 1995 Nov 03; 191(11):1122-32. PubMed ID: 8822114
    [Abstract] [Full Text] [Related]

  • 20. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.
    Trock BJ, Leonessa F, Clarke R.
    J Natl Cancer Inst; 1997 Jul 02; 89(13):917-31. PubMed ID: 9214671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.